ALLO Allogene Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Allogene Therapeutics, Inc. (ALLO) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 12, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on April 15, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Allogene Therapeutics, Inc. (ALLO) (SEC CIK 1737287), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Allogene Therapeutics, Inc. (ALLO) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $243K | $95K | $22K | $0 |
| Operating Income | -$335.4M | -$327.7M | -$273.2M | -$209.3M |
| Net Income | -$1.2B | -$1.6B | -$257.6M | -$190.9M |
| Op. Margin | -138044.9% | -344986.3% | -1241813.6% | — |
| Net Margin | -508642.0% | -1644421.1% | -1170863.6% | — |
| Balance Sheet | ||||
| Total Assets | $817.1M | $642.8M | $548.7M | $415.9M |
| Equity | $665.9M | $512.2M | $422.2M | $292.5M |
| ROE | -185.6% | -305.0% | -61.0% | -65.3% |
Source: XBRL financial data from Allogene Therapeutics, Inc. (ALLO) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 15, 2026 | — | — | — |
8-K | Apr 13, 2026 | — | — | — |
8-K | Apr 13, 2026 | — | — | — |
8-K | Mar 12, 2026 | — | Analysis | — |
10-K | Mar 12, 2026 | Dec 31, 2025 | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 13, 2025 | Jun 30, 2025 | — | |
10-Q | May 13, 2025 | Mar 31, 2025 | — | |
10-K | Mar 13, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | — | |
10-Q | May 13, 2024 | Mar 31, 2024 | — | |
10-K | Mar 14, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 2, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 2, 2023 | Jun 30, 2023 | — | |
10-Q | May 3, 2023 | Mar 31, 2023 | — | |
10-K | Feb 28, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 2, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Feb 23, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 4, 2021 | Jun 30, 2021 | — | |
10-Q | May 5, 2021 | Mar 31, 2021 | — | |
10-K | Feb 25, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest ALLO SEC filings in 2026?
Allogene Therapeutics, Inc. (ALLO) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on April 15, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ALLO file its most recent 10-K annual report?
Allogene Therapeutics, Inc. (ALLO) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ALLO 10-Q quarterly reports?
Allogene Therapeutics, Inc. (ALLO)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every ALLO 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ALLO filed recently?
Allogene Therapeutics, Inc. (ALLO)'s most recent 8-K was filed on April 15, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ALLO insider trading activity (Form 4)?
SignalX aggregates every ALLO Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ALLO file with the SEC?
Allogene Therapeutics, Inc. (ALLO) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ALLO filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Allogene Therapeutics, Inc. (ALLO).
What is ALLO's SEC CIK number?
Allogene Therapeutics, Inc. (ALLO)'s SEC CIK (Central Index Key) number is 1737287. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1737287 to look up all ALLO filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ALLO return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Allogene Therapeutics, Inc. (ALLO) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Allogene Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 34+ filings.